Canada
LightIntegra Technology, founded in 2009, was a biotechnology firm headquartered in Canada. Although the company is CLOSED, its innovative contributions to healthcare, specifically in Medical Devices, leave a significant mark.
The company's flagship product, ThromboLUX, offered an advanced solution for Hematologist-Oncologists, Transfusion Medicine Physicians, and Blood Banks. This device played a crucial role in platelet management by determining the activation status of a platelet sample in just five minutes, thus improving transfusion outcomes.
In terms of investment, the last known financial backing for LightIntegra was a $500.00K venture round investment, occurring on 02 June 2020. This investment was spearheaded by Genome British Columbia.
Despite its closure, LightIntegra exemplified how strategic innovation in biotechnology and healthcare can potentially transform patient care through technological advancements.
